1. Home
  2. AYTU vs UGRO Comparison

AYTU vs UGRO Comparison

Compare AYTU & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • UGRO
  • Stock Information
  • Founded
  • AYTU N/A
  • UGRO 2014
  • Country
  • AYTU United States
  • UGRO United States
  • Employees
  • AYTU N/A
  • UGRO N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • UGRO Industrial Specialties
  • Sector
  • AYTU Health Care
  • UGRO Consumer Discretionary
  • Exchange
  • AYTU Nasdaq
  • UGRO Nasdaq
  • Market Cap
  • AYTU 15.0M
  • UGRO 15.8M
  • IPO Year
  • AYTU N/A
  • UGRO N/A
  • Fundamental
  • Price
  • AYTU $2.36
  • UGRO $1.48
  • Analyst Decision
  • AYTU
  • UGRO Strong Buy
  • Analyst Count
  • AYTU 0
  • UGRO 2
  • Target Price
  • AYTU N/A
  • UGRO $5.63
  • AVG Volume (30 Days)
  • AYTU 29.1K
  • UGRO 18.6K
  • Earning Date
  • AYTU 11-12-2024
  • UGRO 11-07-2024
  • Dividend Yield
  • AYTU N/A
  • UGRO N/A
  • EPS Growth
  • AYTU N/A
  • UGRO N/A
  • EPS
  • AYTU N/A
  • UGRO N/A
  • Revenue
  • AYTU $81,002,000.00
  • UGRO $70,320,066.00
  • Revenue This Year
  • AYTU N/A
  • UGRO $14.76
  • Revenue Next Year
  • AYTU N/A
  • UGRO $21.29
  • P/E Ratio
  • AYTU N/A
  • UGRO N/A
  • Revenue Growth
  • AYTU N/A
  • UGRO 12.08
  • 52 Week Low
  • AYTU $2.20
  • UGRO $1.02
  • 52 Week High
  • AYTU $3.50
  • UGRO $2.84
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 44.84
  • UGRO 59.20
  • Support Level
  • AYTU $2.26
  • UGRO $1.27
  • Resistance Level
  • AYTU $2.47
  • UGRO $1.55
  • Average True Range (ATR)
  • AYTU 0.15
  • UGRO 0.09
  • MACD
  • AYTU -0.01
  • UGRO 0.02
  • Stochastic Oscillator
  • AYTU 16.10
  • UGRO 78.79

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

About UGRO urban-gro Inc.

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

Share on Social Networks: